177Lu-FAP-2286与225Ac-FAP-2286治疗伴淋巴结转移的胰腺腺癌
本文报告一例37岁低分化胰腺腺癌伴淋巴结转移女性患者,在接受1周期吉西他滨联合白蛋白结合型紫杉醇后复发,随后接受3周期177Lu-FAP-2286联合6周期吉西他滨加白蛋白结合型紫杉醇治疗,之后再接受2周期225Ac-FAP-2286治疗。随访68Ga-FAP-2286 PET/CT显示病灶代谢完全缓解,未报告严重不良反应。
要点
- FAP是诊疗一体化的有前景分子靶点。
- 该例接受177Lu-FAP-2286和225Ac-FAP-2286序贯治疗。
- 随访68Ga-FAP-2286 PET/CT示病灶代谢完全缓解。
核心结论
- 该例伴淋巴结转移的胰腺腺癌患者经177Lu-FAP-2286与225Ac-FAP-2286治疗后,68Ga-FAP-2286 PET/CT显示病灶代谢完全缓解,未报告严重不良反应。
研究设计与样本
- 本文为单例病例报告,患者为37岁女性低分化胰腺腺癌伴淋巴结转移。
主要发现
- 患者接受1周期吉西他滨联合白蛋白结合型紫杉醇后于一年前复发。
- 患者接受3周期177Lu-FAP-2286联合6周期吉西他滨加白蛋白结合型紫杉醇治疗,之后接受2周期225Ac-FAP-2286治疗。
- 随访68Ga-FAP-2286 PET/CT显示病灶代谢完全缓解,未报告严重不良反应。
临床怎么用
- FAP靶向放射性核素治疗可作为伴淋巴结转移胰腺腺癌的诊疗一体化探索方向。
局限性
- 本文为单例病例报告,结论不能外推至总体人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fibroblast activation protein (FAP) has emerged as a promising molecular target for theranostic strategies. Here is a case of a 37-year-old woman with poorly differentiated pancreatic adenocarcinoma with lymph node metastasis who received 1 cycle of gemcitabine plus nab-paclitaxel, but relapsed a year ago. She then received 3 cycles of 177Lu-FAP-2286 treatment, in combination with 6 cycles of gemcitabine plus nab-paclitaxel therapy. After that, the patient received an additional 2 cycles of 225Ac-FAP-2286 treatment. A follow-up 68Ga-FAP-2286 PET/CT scan revealed complete metabolic response of the lesions, and no severe adverse reactions were reported.
引用
- Tian C, Mou L, Xu T, et al. Efficacy of 177Lu-FAP-2286 and 225Ac-FAP-2286 in Treating Pancreatic Adenocarcinoma With Lymph Node Metastasis. Clin Nucl Med. 2026. PMID: 41921933. doi:10.1097/RLU.0000000000006373
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。